Home > Insider Trading > Filing (0001209191-20-009847)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1501756	Adverum Biotechnologies Inc.	ADVM	Biological Products, (No Disgnostic Substances) (2836)	205258327

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1614875	Mehdi Gasmi	C/O Adverum Biotechnologies, Inc. 1035 O'Brien Drive Menlo Park CA 94025		Yes	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2020-01-15	88,496	$0.00	321,418	No	4	A	Direct
Common Stock	Disposition	2020-02-12	31,451	$11.33	289,967	No	4	F	Direct
Common Stock	Disposition	2020-02-12	15,494	$15.05	258,979	No	4	F	Direct
Common Stock	Acquisiton	2020-02-12	10,000	$4.80	268,979	No	4	M	Direct
Common Stock	Disposition	2020-02-12	10,000	$15.07	258,979	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	A	Direct
No	4	F	Direct
No	4	F	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Disposition	2020-02-12	10,000	$0.00	10,000	$4.80

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
178,000		2026-02-11	No	4	M	Direct

Footnotes

Represents shares of Common Stock issued upon vesting of restricted stock units with performance-based vesting pursuant to the Separation Agreement between the Reporting Person and Issuer, dated July 30, 2019.
Reflects shares withheld by the Issuer upon vesting of restricted stock units to satisfy withholding tax obligations.
Shares sold pursuant to a 10b5-1 plan.
Price reported is a weighted-average sales price. The shares were sold at prices ranging from $15.00 to $15.13. The reporting person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price.
Twenty-five percent (25%) of the total number of shares subject to the option vest and become exercisable on the first anniversary of the Vesting Commencement Date, and 1/48th of the total number of shares subject to the option vest and become exercisable each month thereafter, such that all of the shares subject to the option shall become vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service with the Issuer on each such vesting date.